Growing evidence suggests a link between maternal infection during pregnancy – including COVID-19 – and an increased risk of neurodevelopmental disorders in children, even in the absence of direct infection in the fetus. Recent studies analyzing data from the COVID-19 pandemic have identified elevated rates of neurodevelopmental issues in children born to mothers who tested positive for SARS-CoV-2 during pregnancy.
Researchers, led by A.G. Edlow, and V.M. Castro, analyzed data from over 18,000 children born during the pandemic, following them until they reached 18 months of age. Their findings, published in JAMA Network Open, indicated a higher risk of neurodevelopmental disorders among the 883 children whose mothers had a positive RT-PCR test during pregnancy. These disorders included psychomotor delays, speech impairments, and learning difficulties. The risk was notably more pronounced in boys and tended to be identified before the age of one year, diminishing somewhat by 18 months.
Further supporting these findings, a study led by L.L. Shook examined health data collected up to age three for over 18,000 children born between March 2020 and May 2021. The study, published in American Journal of Obstetrics & Gynecology, revealed that 16.3% of children exposed to maternal SARS-CoV-2 infection exhibited neurodevelopmental disorders, compared to 9.7% of those not exposed. This difference was again more significant in boys and when the maternal infection occurred during the last trimester of pregnancy.
These findings build upon existing knowledge regarding the impact of maternal infections on fetal development. Rubella, cytomegalovirus (CMV), and toxoplasmosis are well-established examples of infections that can have detrimental effects on a developing fetus, prompting screening and preventative measures. The recognition that Zika virus, previously considered largely benign, could cause brain development issues and microcephaly in fetuses infected during the first trimester further underscored the potential risks.
While the studies highlight a potential association between COVID-19 and neurodevelopmental outcomes, researchers caution that further investigation is needed to establish a definitive causal link. The observed effects may not be directly caused by the virus itself crossing the placenta – which has not been consistently demonstrated – but rather by an activation of the maternal immune system and subsequent inflammation at the placental level and within the fetus. This inflammatory response could potentially disrupt brain development, leading to long-term neurological consequences.
Recent experimental research conducted at the Rega Institute of KU Leuven in Belgium, using a hamster model, supports the inflammation hypothesis. Researchers found that COVID-19-related inflammation of the placenta led to impaired fetal growth. Although the virus was not transmitted to the embryos, viral RNA was detected transiently in the placentas, which exhibited signs of damage, including thrombosis and increased levels of inflammatory molecules. Preventative vaccination of the hamsters and anticoagulant treatment were shown to mitigate these effects.
A key consideration in this evolving understanding is the potential role of the immune response to infection, rather than the infection itself, in contributing to fetal development issues. Vaccination, which elicits an immune response without the full intensity or uncontrolled nature of an active infection, is being investigated for its potential impact. Current evidence, including analyses by the World Health Organization, does not indicate a causal link between vaccines and autism. Many vaccines are considered safe for administration during pregnancy, particularly those offering protection to both mother and child through antibody transfer.
The studies on COVID-19 and neurodevelopmental outcomes are ongoing, and researchers emphasize the demand for longer-term, prospective studies to fully understand the potential risks and identify strategies for prevention and intervention. The Rega Institute study identified placental inflammation as a potential therapeutic target in cases of maternal infection, but further research is required to determine the most effective approaches.
